Treatment of Diabetic Neuropathy with Gamma-linolenic Acid.
The Gamma-Linolenic Acid Multicenter Trial Group
Diabetes Care 1993 (Jan); 16 (1): 8–15
We entered 111 patients with mild diabetic neuropathy from seven centers into a randomized, double-blind, placebo-controlled parallel study of GLA at a dose of 480 mg/day. MNCV, SNAP, CMAP, hot and cold thresholds, sensation, tendon reflexes, and muscle strength were assessed by standard tests in upper and lower limbs.